Neutrophil extracellular traps in ulcerative colitis: A proteome analysis of intestinal biopsies

Inflammatory Bowel Diseases

Volumn 21, Issue 9, 2015, Pages 2052-2067

  Bennike, Tue Bjerg ^a,b,c   Carlsen, Thomas Gelsing ^a   Ellingsen, Torkell ^d   Bonderup, Ole Kristian ^e,f   Glerup, Henning ^e   Bøgsted, Martin ^a,g   Christiansen, Gunna ^f   Birkelund, Svend ^a   Stensballe, Allan ^a   Andersen, Vibeke ^b,c,h  

^a AALBORG UNIVERSITY   (Denmark)

^b Hospital of Southern Jutland   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e SILKEBORG REGIONAL HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h VIBORG HOSPITAL   (Denmark)

Author keywords

Inflammatory bowel diseases; Microscopy; Neutrophil extracellular traps; Proteomics; Ulcerative colitis

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; AZATHIOPRINE; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; CATHEPSIN G; CHITINASE 3 LIKE PROTEIN 1; DERLIN 3; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PEROXIDASE; GALECTIN; GELATINASE B; HEXOKINASE 3; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN ASPART; INTEGRIN ALPHA M; LACTOFERRIN; LEUKOCYTE ELASTASE; MAST CELL EXPRESSED MEMBRANE PROTEIN 1; MESALAZINE; MYELOBLASTIN; MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEPTIDOGLYCAN RECOGNITION PROTEIN 1; PREDNISONE; PROTEIN S 100; STEFIN A; TRANSMEMBRANE PROTEIN 179B; UNCLASSIFIED DRUG; PROTEOME;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON; COLON BIOPSY; COLONOSCOPY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; EXTRACELLULAR TRAP; FEMALE; HIGH THROUGHPUT SCREENING; HISTOLOGY; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; INTESTINE BIOPSY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEOMICS; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; ULCERATIVE COLITIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BIOPSY; CASE CONTROL STUDY; CHEMISTRY; FECES; GENETICS; IMMUNOLOGY; INTESTINE; METABOLISM; NEUTROPHIL; PATHOLOGY; PROCEDURES;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; EXTRACELLULAR TRAPS; FECES; FEMALE; HUMANS; IMMUNITY, INNATE; INTESTINES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; NEUTROPHILS; PROTEOME; PROTEOMICS;

EID: 84940952713     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000460     Document Type: Article

References (75)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42.
2. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728.
3. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11:43-48.
4. Jussila A, Virta LJ, Pukkala E, et al. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J Crohns Colitis. 2014;8:1088-1096.
5. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
6. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325.
7. Ehrentraut SF, Colgan SP. Implications of protein post-translational modifications in IBD. Inflamm Bowel Dis. 2012;18:1378-1388.
8. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17:831-848.
9. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
10. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
11. Bennike T, Birkelund S, Stensballe A, et al. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014;20:3231-3244.
12. Tontini GE, Vecchi M, Pastorelli L, et al. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015;21:21-46.
13. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-1314.
14. Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol. 2009; 33(suppl 3):S158-S173.
15. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113-123.
16. Steinbakk M, Naess-Andresen C-F, Fagerhol MK, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990;336:763-765.
17. Hsieh SY, Shih TC, Yeh CY, et al. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics. 2006;6:5322-5331.
18. Poulsen NA, Andersen V, Møller JC, et al. Comparative analysis of inflamed and non-inflamed colon biopsies reveals strong proteomic inflammation profile in patients with ulcerative colitis. BMC Gastroenterol. 2012;12:76.
19. Camerini S, Mauri P. The role of protein and peptide separation before mass spectrometry analysis in clinical proteomics. J Chromatogr A. 2015; 1381:1-12.
20. Han NY, Choi W, Park JM, et al. Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease. J Dig Dis. 2013;14:166-174.
21. Krzywinski M, Altman N. Points of significance: comparing samples-part II. Nat Methods. 2014;11:355-356.
22. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
23. Fernández-Bañares F, Casalots J, Salas A, et al. Paucicellular lymphocytic colitis: is it a minor form of lymphocytic colitis? A clinical pathological and immunological study. Am J Gastroenterol. 2009;104:1189-1198.
24. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-675.
25. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology. 1998;115:525-532.
26. Leon IR, Schwammle V, Jensen ON, et al. Quantitative assessment of in-solution digestion efficiency identifies optimal protocols for unbiased protein analysis. Mol Cell Proteomics. 2013;12:2992-3005.
27. Wisniewski JR, Zougman A, Nagaraj N, et al. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359-362.
28. Manza LL, Stamer SL, Ham AJL, et al. Sample preparation and digestion for proteomic analyses using spin filters. Proteomics. 2005;5:1742-1745.
29. Masuda T, Tomita M, Ishihama Y. Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J Proteome Res. 2008;7:731-740.
30. Urbaniak GC, Plous S. Research Randomizer (Version 4.0) [computer software]. 2013. Available at: http://www.randomizer.org/. Accessed October 10, 2013.
31. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotech. 2008;26:1367-1372.
32. Cox J, Neuhauser N, Michalski A, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011; 10:1794-1805.
33. Bennike T, Ayturk U, Haslauer CM, et al. A normative study of the synovial fluid proteome from healthy porcine knee joints. J Proteome Res. 2014;13:4377-4387.
34. Bennike T, Lauridsen KB, Olesen MK, et al. Optimizing the identification of citrullinated peptides by mass spectrometry: utilizing the inability of trypsin to cleave after citrullinated amino acids. J Proteomics Bioinform. 2013;06:288-295.
35. Deeb SJ, D'Souza RCJ, Cox J, et al. Super-silac allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics. 2012;11:77-89.
36. Bhatia VN, Perlman DH, Costello CE, et al. Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. Anal Chem. 2009;81:9819-9823.
37. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116-5121.
38. Hubner NC, Bird AW, Cox J, et al. Quantitative proteomics combined with BAC TransgeneOmics reveals in vivo protein interactions. J Cell Biol. 2010;189:739-754.
39. Murgia M, Nagaraj N, Deshmukh AS, et al. Single muscle fiber proteo-mics reveals unexpected mitochondrial specialization. EMBO Rep. 2015; 16:387-395.
40. Vizcaíno JA, Deutsch EW, Wang R, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014;32:223-226.
41. Vizcaíno JA, Côté RG, Csordas A, et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013;41:D1063-D1069.
42. Fournier BM, Parkos CA. The role of neutrophils during intestinal inflammation. Mucosal Immunol. 2012;5:354-366.
43. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol. 2012;198:773-783.
44. Rao PK, Li Q. Principal component analysis of proteome dynamics in iron-starved mycobacterium tuberculosis. J Proteomics Bioinform. 2009; 2:19-31.
45. O'Donoghue AJ, Jin Y, Knudsen GM, et al. Global substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by Elastase Glogauer M, ed. PLoS One. 2013; 8:e75141.
46. Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519-531.
47. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-1535.
48. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity ulcerative colitis than Lichtiger Index, C-reactive protein platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341.
49. Vos MD, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements predict relapse patients ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111-2117.
50. Barceló-Batllori S, André M, Servis C, et al. Proteomic analysis of cyto-kine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics. 2002;2:551-560.
51. Munn DH, Mellor AL. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34:137-143.
52. Schmidt SV, Schultze JL. New insights into IDO biology in bacterial and viral infections. Front Immunol. 2014;5:384.
53. Shkoda A, Werner T, Daniel H, et al. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. JProteome Res. 2007;6:1114-1125.
54. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007; 42:1321-1331.
55. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36.
56. Lu X, Wang M, Qi J, et al. Peptidoglycan recognition proteins are a new class of human bactericidal proteins. J Biol Chem. 2006;281:5895-5907.
57. Liu C, Xu Z, Gupta D, et al. Peptidoglycan recognition proteins a novel family of four human innate immunity pattern recognition molecules. J Biol Chem. 2001;276:34686-34694.
58. Furuta H, Nishi S, Le Beau MM, et al. Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (HK3) to chromosome band 5q35.2 by fluorescence in situ hybridization. Genomics. 1996;36:206-209.
59. Lowes W, Walker M, Alberti KG, et al. Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis. Bio-chim Biophys Acta. 1998;1379:134-142.
60. Rosenfeld G, Bressler B. The truth about cigarette smoking and the risk of inflammatory bowel disease. Am J Gastroenterol. 2012;107:1407-1408.
61. Higuchi LM, Khalili H, Chan AT, et al. A Prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107:1399-1406.
62. Abraham C, Cho JH. Inflammatory bowel disease. NEngl J Med. 2009; 361:2066-2078.
63. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462-1471.
64. García Rodríguez LA, González-Pérez A, Johansson S, et al. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther. 2005;22:309-315.
65. Lindberg E, Tysk C, Andersson K, et al. Smoking and inflammatory bowel disease. A case control study. Gut. 1988;29:352-357.
66. Khor TS, Fujita H, Nagata K, et al. Biopsy interpretation of colonic biopsies when inflammatory bowel disease is excluded. J Gastroenterol. 2012;47:226-248.
67. Geboes K. Histopathology of Crohn's disease and ulcerative colitis. In-flamm Bowel Dis. 2003:255-276.
68. Branzk N, Lubojemska A, Hardison SE, et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol. 2014;15:1017-1025.
69. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol. 2011;17:557-566.
70. Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93:97-108.
71. Beiter T, Fragasso A, Hartl D, et al. Neutrophil extracellular traps: a walk on the wild side of exercise immunology. Sports Med. 2015;45:625-640.
72. Beiter T, Fragasso A, Hudemann J, et al. Neutrophils release extracellular DNA traps in response to exercise. J Appl Physiol (1985). 2014; 117:325-333.
73. Stephan A, Fabri M. The NET, the trap, and the pathogen: neutrophil extracellular traps in cutaneous immunity. Exp Dermatol. 2014;24: 161-166.
74. Vester-Andersen MK, Vind I, Prosberg MV, et al. Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011-a Danish population-based cohort study. JCrohns Colitis. 2014;8: 1675-1683.
75. Reich KM, Chang H-J, Rezaie A, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014;40:629-638.